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-------------------------------------------------------------------------------------------------------, 
We investigated the tumor-suppressor gene, TP53, in psori-
atic skin at gene (GP53) and protein (p53) levels. No muta-
tion was detected in the seven exons analyzed using a combi-
nation of polymerase chain reaction and single-strand 
conformation polymorphism techniques. In addition, by im-
munohistochemistry using three different anti-p53 antibod-
ies, no positive staining, reported to be associated with muta\ 
tions and/or abnormal expression of the TP53 gene, w~ 
observed in psoriatic skin biopsies, in contrast to recent re\ 
ports. These results suggest that the proliferative status ot 
psoriatic keratinocytes does not implicate the TP53 gene, 
] Invest Dermato!101:100-102, 1993 
-------------------------------------------------------------------------------------------------------, 
Psoriasis is a benign skin disease with a complex inheri-tance pattern, characterized by hyperproJiferation (1,2J and abnormal differentiation [3,4J of keratinocytes. Many genes, earticularly oncogenes (5) and tumor-sup-pressor genes [6), can be involved in dysregulation of the 
cell-cycling process. It is well known that oncogenes can stimulate 
and promote cell division, whereas tumor-suppressor genes are de-
fined as being genes that can repress cell proliferation. Inactivation 
of the TP53 tumor-suppressor gene by point mutations and/or alle-
lic loss actually represents the most frequent genomic alteration in 
human cancers (for review see [7]). However, the cellular function 
of the gene product p53 as well as the way by which it acts is still 
unclear (8] . 
There has been recent interest in studies of p53 alterations in 
benign diseases such as psoriasis. Tadini and co-workers reported 
abnormal nuclear p53 immunohistochemical staining in the basal 
layer of lesional psoriatic skin (9]. This suggests th~ occurrence of 
TP53 gene alterations in psoriasis, because the half-hfe of a mutated 
p53 protein was shown to be prolonged in vitro [10]. 
In the present study, we looked for mut~tions i~ the ~P53. gene in 
a series of 15 extracted DNAs from skm psonatlc bIOpSies by a 
combination of polymerase chain reaction (PCR) and single-
stranded conformation polymorphism (SSCP). Moreover, p53 ex-
pression was investigated in 12 psoriatic skin biopsies by immuno-
histochemical analysis. 
MATERIALS AND METHODS 
Patients Fifteen 4-mm punch biopsies from eight psoriatic pa-
tients (eight lesional and seven non-lesionaJ psoriatic skin biopsies) 
were collected for DNA extraction at the Dermatological Depart-
ment of the H6pital Saint Charles (Montpellier, France). Two of 
these, and ten additionallesional psoriatic skin 4-mm punch biop-
sies were collected to obtain tissue sections for immunohistochemi-
cal analysis. After surgical excision, all samples were rapidly frozen 
in liquid nitrogen and subsequently stored at - 80°C until used. 
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DNA Extraction and PCR-SSCP Analysis Genomic ON~ 
from psoriatic skin were extracted from powdered punch biopsie, 
(4 mm) using the phenol/chloroform method as previously de, 
scribed [11]. Radioactive PCRs were performed for 35 cycles cou, 
sisting of 30 seconds at 94 ° C, 20 seconds in a temperature range ot 
40-63°C depending on the primers and 1 min at noc. Regio~ 
screened covered exon 2 and exons 4 through 9 (Fig 1). The SSCI< 
analysis was performed according to the technique described b)' 
Spinardi et al [12]. Briefly, PCR products were diluted in loadin& 
buffer (95% formamide, 5% ethylenediaminetetraacetic aci~ 
0.5 M, 0.025% bromophenol blue, 0.025% xylene cyanol blue), 
heat denatured, and loaded onto 4.5% or 6% non-denaturing aery, 
lamide gel containing or not containing 5% glycerol. Gels were fUlt 
at constant power and at room temperature for those containing 
glycerol or at 4 ° C for those without glycerol. After migration, gels 
were subjected to autoradiography against a Kodak XAR-5 film at 
-80°e. Couples of primers used for TP53 gene analysis were as 
follows [13]: exon 2, 5'-TGCAGCAGCTAGACTGCCTTCC; 
3'-CAATGGATCCACTCACAGTTTCC; 3' end of the exon 4, 
5' - TGCACCAGCAGCTCCT ACAC/3' - CATGGAAGCCAG-
CCCCTCAG; exon 5, 5'-GCCGTGTTCCAGTTGCTTT ATC/ 
3' -GT AGATGGCCATGGCGCGGACG; exon 5',5' -GTGGAT-
TCCACACCCCCGCCCGG/3' -TCAGTGAGGAA TCAGAG-
GCC; exon 6, 5' -CTGGAGAGACGACAGGGCTG /3' -GCCA-
CTGACAACCACCCTTA; exon 7, 5' -CCTCATCTTGGGCC-
TGTGTT/3'-TCAGCGGCAAGCAGAGGCTG; exon 8-9, 5'-
AGGACCTGATTTCCTTACTG/3' - CTTTCCACTTGATA-
AGAGGTe. 
Reagents Three different anti-p53 antisera were used: polyclonal 
antibody (PoAb) CM!, mOlloclonal antibody (MoAb) D07 (Novo-
castra, UK) and MoAb 1801 (Oncogene Science, USA). All of these 
antibodies recognized both the wild-type and mutated form of the 
p53 protein. The epitopes of both D07 and 1801 MoAbs were 
located in the NH2-terminal portion of the protein, and the CM1 
PoAb was raised against a recombinant wild-type p53 protein. 
Immunohistochemical Analysis Tissue sections (5 f.1.m thick) 
from OCT compound (Miles, USA) -embedded psoriatic skin 
were fixed with acetone/methanol (SO/50, v/v) at -20°e. Anti-
bodies were used at 1/50 dilution and revealed using an avidin-bio-
tin peroxidase complex system according to the manufacturer's in-
structions (OPC, France). The peroxidase reaction was performed 
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Figure 1. Schematic representation of the TP53 gene. White boxes, exons 
analyzed; arrows, the pair of primers used. Black boxes, conserved amino acid 
sequence blocks of the protein. 
with 3-3' -diaminobenzidine chfomogene (Sigma, France); slides 
were then counterstained with Mayer's hemalun (Ral, France). The 
T47D breast cancer cell line and a previously characterized mutated 
basal cell carcinoma [12] were used as positive controls. For negative 
controls, the slides were incubated with a solution of phosphate-
buffered saline/l % bovine serum albumin lacking the first anti-
body. 
RESULTS 
PCR-SSCP Analysis of the TP53 Gene After PCR amplifica-
tion of various portions of the TP53 gene (Fig 1) by PCR, we 
detected point mutations using a SSCP technique based on the con-
formation of the single-stranded DNA [14]. Under non-denaturing 
electrophoretic conditions, migration of single-stranded DNAs is a 
function of their conformation that depends on their sequence. As 
little as a single point mutation can be visualized by a variant migra-
tion pattern (see control DNA in lane C and arrow). An identical 
wild-type migration pattern was observed in all psoriatic DNAs 
including lesional and non-Iesional psoriatic biopsies (Fig 2). How-
ever, a shifted band, thus indicating a point mutation, was detected 
in a previously sequenced mutated basal cell carcinoma DNA used as 
control (Fig 2) . 
Immunohistochemical Analysis of the p53 protein Using 
three anti-p53 antibodies (PoAb CM1, MoAbs D07 and 1801), we 
did not observe any nuclear staining in the 12 biopsies analyzed, 
whereas the positive controls (T47D cell line and a previously de-
scribed mutated basal cell carcinoma) were normally stained (Fig 3) . 
Moreover, five of these frozen specimens covered the edge of a 
psoriatic lesion, and we did not observe any difference in p53 stain-
ing between lesional and the flanking non-lesional skin (Fig 3). 
DISCUSSION 
Alteration of the TP53 tumor sUPJ:Jfessor gene is the most frequent 
event reported in human cancers l7]. TP53 mutations are observed 
with variable incidence in all cancers, including epithelial skin 
cancers. The frequency of mutation is elevated in basal cell carcino-
mas [12] and in squamous cell carcinomas [15,16]. Because TP53 
mutations frequently occur in skin-tumoral processes, they could 
also be involved in psoriatic keratinocyte hyperproliferation. 
In this study, with a combination of PCR and SSCP techniques, 
no mutation of the TP53 gene could be detected in DNAs extracted 
from 15 lesional or non-Iesional psoriatic skins. Exon 2 and exons 4 
through 9 were screened for this study. They correspond to the 
region containing the mutational hot-spot sites described in human 
cancers [17]. These regions also include the coding sequence for the 
most conserved amino acid domains of the protein in all species [18] 
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Figure 2. Results obtained by PCR-SSCP of exon 5 on the TP53 gene. By 
this technique, double-stranded PCR products are heat denatured and the 
single-stranded ONAs (SS) obtained are loaded into a non-denaturing acry-
lamide gel. Odd latles, ONAs extracted from lesional psoriatic skin; evetllalles, 
those extracted from non-Iesional psoriatic skin. Lalles associated w ith a bar 
correspond to ONAs extracted from the same patient. 
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Figure 3. Immunohistochemical results with anti-p53 antibodies. The 
mutated basal cell carcinoma used as positive control is presented on A and 
the negative control slide on B. Absence of staining in a psoriatic skin biopsy 
covering the non-lesional skin and the lesional skin is shown on C and D, 
respectively. Bar, 50 j1m. 
(Fig 1). The method used is empirical and very sensitive because 
diluted mutated DNAs, as low as 10%, can still be easily detected 
(unpublished results) . Because a technique as sensitive as PCR-
SSCP cannot detect all mutations, and although we have not ob-
served any mutations, we cannot totally exclude the possibility that 
TP53 mutations occur in psoriasis, particularly in other parts of the 
gene. 
We also used an immunohistochemical technique to analyze 
TP53 gene expression. With this procedure, positive staining could 
indicate the presence of a mutation in the TP53 gene, because most 
p53-mutated proteins have a prolonged half-life [10]. With three 
commercial antibodies (PoAb CM1, MoAbs D07 and 1801) that 
recognize different epitopes, we did not observe nuclear staining in 
lesional and non-lesional psoriatic skins. Assays were controlled 
with both a positive breast cancer cell line (T47D) and a mutated 
basal cell carcinoma. The absence of p53 staining with these three 
antibodies was in accordance with the absence of genomic muta-
tions in the TP53 gene. 
Nevertheless, Tadini and co-workers reported p53 nuclear stain-
ing in the basal layer oflesional psoriatic skin, using PoAbs 421 and 
1801 [9]. More recently, Helander et al:!: observed p53 cytoplasmic 
staining with MoAb 421 and MoAb 1801 in basal and suprabasal 
layers of psoriatic lesions. These differences in results obtained by 
each group, even though at leas t one identical antibody was used in 
the three studies, underline the difficulty of interpreting immuno-
histochemical results with anti-p53 antibodies. We have found that 
it is very important to use adequate controls so as to avoid fa lse 
interpretations. This is emphasized by the recent observation of 
cross-reactivity of anti-p53 antibodies with other proteins like kera-
tins [19] . Moreover, it has been recently shown that ultraviolet 
:j: Helander SO, Peters MS, Pittelkow MR: p53 expression and localiza-
tion in normal skin, psoriasis, cutaneous carcinoma and cultured keratino-
cytes (abstr). J Invest Oermatol 98:636, 1992. 
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irradiation induces pS3 expression in in vivo normal human skin that 
returns to undetectable basal level within 15 d [20] . As psoriatic 
patients often undergo psoralen plus ultraviolet A therapy, we 
wonder whether this could explain why p53 expression can be 
detected in some instances. It should be kept in mind that detection 
of the p53 protein does not necessarily indicate the existence of a 
mutation of the gene but can also come from a dysregularion of its 
expression. 
In conclusion, the TPS3 gene was not altered in the seven exons 
analyzed, and TP53 gene product was not detected, in psoriatic skin. 
Dysregulation of the cell-cycle process in this disease might come 
from other genes, such as still unstudied tumor-suppressor genes or 
oncogenes; we recently demonstrated a decrease in c-FOS expres-
sion in lesional psoriatic skin [21]. More studies are required to 
understand the possible involvement of oncogene and/or tumor 
suppressor genes in psoriasis. 
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ANNOUNCEMENT 
A workshop on Photoimmunology will be held in Capocaccia, near Alghero, Sardinia, Italy, 
October 8 - 10, 1993. The workshop will take place during the summerschool, entitled Photo-
biology in Medicine. 
Organizers of the Photoimmul1010gy workshop are P. Bergstresser, Th . Dubbelman, and 
BJ. Vermeer. 
The following topics will be discussed. 
1. Introduction immunology of the skin . 
2. Modulation of the immune system by UV light (antigen presentation, T-cell recognition, 
cytokine production, adhesion molecules). 
3. Genetic polymorphism of UV -induced immune suppression. 
4. Photoreceptor for UV-induced immune suppression. 
5. Effect ofUV light on infections (HIV, Herpes simplex). 
6. Clinical relevance of photoimmunology (e.g., skin cancer in immune compromised host). 
7 . Therapeutic use ofUV-induced immunosuppression (e.g., thrombocyte transfusion). 
8. Immunologic aspects of photophoresis and photodynamic therapy. 
9 . Effect of sunscreen on photoimmunological aspects. 
For registration contact B.]. Vermeer, Department of Dermatology, University Hospital, 
Leiden, P.O. Box 9600, 2300 RC Leiden, The Netherlands. Fax: 31 71 144348. 
